Korro Bio, Inc. (KRRO)

The past six months have been volatile for Korro Bio, Inc.'s stock. In August 2025, the company reported its second-quarter financial results, received EMA Orphan Drug Designation for KRRO-110, and noted collaboration revenue from Novo Nordisk. In November 2025, disappointing clinical data from the REWRITE study of KRRO-110 led to a significant stock price decline of over 75% and multiple analyst downgrades. Korro Bio responded with a workforce reduction of approximately 34%, the resignation of its Chief Medical Officer, and a pause in its collaboration with Novo Nordisk. The stock price continued to decline into January 2026.

Korro Bio, Inc. does not currently have established product demand seasonality as its lead product candidates are still in clinical trials and not yet commercialized. Stock seasonality analysis suggests a historical "Buy Date of October 30 and a Sell Date of February 6", but this pertains to stock performance rather than product demand. The available data for stock seasonality is limited to five years, which is insufficient for reliable long-term analysis.

Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing RNA editing-based genetic medicines. The company operates in the Health Technology sector, specifically in Drug Discovery and Biotechnology: Pharmaceutical Preparations. Korro Bio aims to treat rare and prevalent diseases by using the body's RNA editing process for precise, transient single-base edits. Its lead product candidate, KRRO-110, is in Phase 1/2 clinical trials for Alpha-1 Antitrypsin Deficiency (AATD), designed to repair a mutation in the SERPINA1 gene. KRRO-121 is a development candidate for hyperammonemia, including urea cycle disorders (UCD) and hepatic encephalopathy (HE). The company is also developing programs for pain, Parkinson's disease, Amyotrophic lateral sclerosis, and severe drug-associated anesthetics, utilizing its OPERA platform for RNA editing therapies.

Korro Bio, Inc. is headquartered in Cambridge, Massachusetts, United States.

Korro Bio, Inc.'s brand reputation has been significantly impacted, particularly in late 2025. Disappointing clinical trial results for KRRO-110 in November 2025 led to a sharp decline in investor confidence, reflected in the stock price drop and analyst downgrades. The subsequent workforce reduction and the pause in its collaboration with Novo Nordisk further damaged the company's reputation.

Korro Bio, Inc. has a significant number of institutional owners and shareholders. As of recent filings, 179 institutional owners hold a total of 10,210,818 shares. Major institutional owners include Atlas Venture Life Science Advisors, LLC, NEA Management Company, LLC, Driehaus Capital Management LLC, Fmr LLC, Point72 Asset Management, L.P., Cormorant Asset Management, LP, BlackRock, Inc., Siren, L.L.C., TCG Crossover Management, LLC, and Vanguard Group Inc. Other notable institutional holders include JPMorgan Chase & Co., XTX Topco Ltd, Polar Capital Holdings Plc, Millennium Management LLC, Citadel Advisors LLC, Bank of America Corp DE, Algert Global LLC, Alliancebernstein L.P., Schonfeld Strategic Advisors LLC, Raymond James Financial Inc., ADAR1 Capital Management LLC, Two Sigma Investments LP, and F m Investments LLC.